2. Search Result
Search Result
Results for "

Anti-atherosclerotic

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

1

Peptides

19

Natural
Products

2

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0144A
    Pitavastatin
    5+ Cited Publications

    NK-104

    		 HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
    Pitavastatin
  • HY-15589
    GW9508
    5 Publications Verification

    		 Free Fatty Acid Receptor Potassium Channel Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .
    GW9508
  • HY-B0218R
    Orlistat (Standard)
    Maximum Cited Publications
    18 Publications Verification

    Tetrahydrolipstatin (Standard); Ro-18-0647 (Standard)

    		 Reference Standards Fatty Acid Synthase (FASN) Apoptosis Metabolic Disease Cancer
    Orlistat (Standard) is the analytical standard of Orlistat. This product is intended for research and analytical applications. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity . Anti-atherosclerotic effect .
    Orlistat (Standard)
  • HY-118486
    LDL-IN-1

    		Acyltransferase Metabolic Disease
    LDL-IN-1 (Compound 1) is an antioxidant, and is active against copper mediated LDL oxidation (IC50 = 52 μM). LDL-IN-1 is also an Acyl-CoA:cholesterol acyltransferase-1 and -2 (ACAT-1/2) inhibitor, with IC50s of 60 μM. LDL-IN-1 can be used for anti-atherosclerotic research .
    LDL-IN-1
  • HY-116150
    Xymedon

    		Others Cardiovascular Disease
    Xymedon is a pyrimidine derivative with anti-atherosclerotic effects. Xymedon reducts plasma cholesterol levels and cholesterol esterification in blood vascular cells .
    Xymedon
  • HY-119265
    LDL-IN-4

    		Acyltransferase Metabolic Disease
    LDL-IN-4 (Compound 2) inhibits human acyl-CoA:cholesterol acyltransferase-1 and -2 activities. LDL-IN-4 inhibits copper-mediated low density lipoprotein (LDL) oxidation, with an IC50 of 3 μM. LDL-IN-4 has anti-atherosclerotic biological activity .
    LDL-IN-4
  • HY-B0144B
    Pitavastatin sodium

    NK-104 sodium

    		 HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
    Pitavastatin sodium
  • HY-N13869
    Asperlin

    		Antibiotic Bacterial Apoptosis Reactive Oxygen Species (ROS) Bcl-2 Family NO Synthase COX TNF Receptor Interleukin Related Infection Metabolic Disease Inflammation/Immunology Cancer
    Asperlin is an orally active marine-derived antibiotic with antifungal, anticancer, anti-inflammatory and anti-atherosclerotic activities. Asperlin induces apoptosis. Asperlin increases reactive oxygen species (ROS)- and DNA damage-associated G2/M phase arrest and ATM phosphorylation. Asperlin is effective in preventing HFD-induced obesity and modulating gut microbiota .
    Asperlin
  • HY-U00054
    LDL-IN-3

    		LDLR Cardiovascular Disease Metabolic Disease
    LDL-IN-3 is an anti-atherosclerotic compound extracted from patent WO/2005/039596A1, example C25 and patent US 6133467, example 3.
    LDL-IN-3
  • HY-15589R
    GW9508 (Standard)

    		Free Fatty Acid Receptor Potassium Channel Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    GW9508 (Standard) is the analytical standard of GW9508. This product is intended for research and analytical applications. GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .
    GW9508 (Standard)
  • HY-173230
    ABCA1 inducer 2

    		ATP-binding cassette (ABC) transporters LXR Cardiovascular Disease
    ABCA1 inducer 2 is a non-lipotropic ABCA1 inducer. ABCA1 inducer 2 upregulates the expression of ABCA1 by targeting the LXR pathway. ABCA1 inducer 2 can reduce ox-LDL-induced lipid accumulation and thus inhibit foam cell formation. ABCA1 inducer 2 has anti-atherosclerotic potential .
    ABCA1 inducer 2
  • HY-14928
    Lobeglitazone

    		PPAR ERK JNK TGF-beta/Smad NO Synthase COX NF-κB Interleukin Related Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone is the orally active agonist for PPAR with EC50 of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties .
    Lobeglitazone
  • HY-14928A
    Lobeglitazone sulfate

    		PPAR ERK JNK TGF-beta/Smad NO Synthase COX NF-κB Interleukin Related Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate is the orally active agonist for PPAR with EC50 of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone sulfate is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties .
    Lobeglitazone sulfate
  • HY-N0403
    2,3,4',5-Tetrahydroxystilbene 2-O-β-D-glucoside

    		Apoptosis Inflammation/Immunology
    2,3,4',5-Tetrahydroxystilbene 2-O-β-D-glucoside (TSG) is an active product that can be extracted from Polygonum multiflorum Thunb. TSG has anti-inflammatory, antioxidative, anti-atherosclerotic, anti-apoptotic, and free radical scavenging activities, TSG is also indicated to facilitate long-term potentiation and learning and memory in both normal and pathological conditions .
    2,3,4',5-Tetrahydroxystilbene 2-O-β-D-glucoside
  • HY-110247
    TRAF-STOP inhibitor 6877002
    1 Publications Verification

    		 TNF Receptor NF-κB Cardiovascular Disease Inflammation/Immunology
    TRAF-STOP inhibitor 6877002 is a selective CD40-TRAF6 interaction inhibitor. TRAF-STOP inhibitor 6877002 exerts anti-atherosclerotic activity by blocking the CD40-TRAF6 signaling pathway, inhibiting classical monocyte activation, leukocyte recruitment, and macrophage activation and migration. TRAF-STOP inhibitor 6877002 reduces the phosphorylation levels of signaling intermediates in the canonical NF-κB pathway .
    TRAF-STOP inhibitor 6877002
  • HY-132591
    Inclisiran
    2 Publications Verification

    ALN-PCSsc

    		 PCSK9 Small Interfering RNA (siRNA) Pyroptosis PPAR NOD-like Receptor (NLR) Caspase Interleukin Related Cardiovascular Disease Metabolic Disease
    Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .
    Inclisiran
  • HY-132591A
    Inclisiran sodium
    2 Publications Verification

    ALN-PCSsc sodium

    		 PCSK9 Small Interfering RNA (siRNA) Pyroptosis PPAR NOD-like Receptor (NLR) Caspase Interleukin Related Cardiovascular Disease Metabolic Disease
    Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .
    Inclisiran sodium
  • HY-N4247
    Kuwanon G

    		Bombesin Receptor Bacterial Apoptosis Reactive Oxygen Species (ROS) PI3K Akt GSK-3 MMP mTOR NF-κB LXR Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Kuwanon G is a flavonoid compound and an antagonist of the bombesin receptor. Kuwanon G has multiple activities such as bactericidal, anti-tumor, anti-inflammatory, antioxidant, anti-atherosclerotic, and neuroprotective effects. Kuwanon G exhibits strong antibacterial activity against oral pathogens, especially cariogenic bacteria and periodontal pathogens. Kuwanon G can induce apoptosis and inhibit proliferation, migration, and invasion of tumor cells. Kuwanon G can be used in the research of diseases such as gastric cancer and atherosclerosis .
    Kuwanon G
  • HY-B0144
    Pitavastatin Calcium
    5+ Cited Publications

    NK-104 hemicalcium; Pitavastatin hemicalcium

    		 HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
    Pitavastatin Calcium
  • HY-N4247R
    Kuwanon G (Standard)

    		Reference Standards Bombesin Receptor Bacterial Apoptosis Reactive Oxygen Species (ROS) PI3K Akt GSK-3 MMP mTOR NF-κB LXR Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Kuwanon G (Standard) is the analytical standard of Kuwanon G (HY-N4247). This product is intended for research and analytical applications. Kuwanon G is a flavonoid compound and an antagonist of the bombesin receptor. Kuwanon G has multiple activities such as bactericidal, anti-tumor, anti-inflammatory, antioxidant, anti-atherosclerotic, and neuroprotective effects. Kuwanon G exhibits strong antibacterial activity against oral pathogens, especially cariogenic bacteria and periodontal pathogens. Kuwanon G can induce apoptosis and inhibit proliferation, migration, and invasion of tumor cells. Kuwanon G can be used in the research of diseases such as gastric cancer and atherosclerosis .
    Kuwanon G (Standard)
  • HY-B0144R
    Pitavastatin Calcium (Standard)

    NK-104 hemicalcium (Standard); Pitavastatin hemicalcium (Standard)

    		 Reference Standards HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Pitavastatin (Calcium) (Standard) is the analytical standard of Pitavastatin (Calcium). This product is intended for research and analytical applications. Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
    Pitavastatin Calcium (Standard)
  • HY-137390A
    (3S,5R)-Fluvastatin potassium

    		HMG-CoA Reductase (HMGCR) Cardiovascular Disease Metabolic Disease
    (3S,5R)-Fluvastatin (potassium) is a synthetic hypolipidemic drug that inhibits HMG-CoA reductase activity. (3S,5R)-Fluvastatin (potassium) has similar antioxidative effects on copper ion-induced LDL oxidation compared to its 3R,5S enantiomer. (3S,5R)-Fluvastatin (potassium) and its metabolites demonstrate a potential to exhibit anti-atherosclerotic effects through their antioxidative activities. (3S,5R)-Fluvastatin (potassium) is clinically utilized as part of a racemic mixture for reducing plasma cholesterol levels.
    (3S,5R)-Fluvastatin potassium
  • HY-N1934
    Dihydroberberine

    		Potassium Channel HSP Cardiovascular Disease Inflammation/Immunology Cancer
    Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .
    Dihydroberberine
  • HY-129440
    N-(p-Coumaroyl) Serotonin

    		PDGFR ERK Caspase Metabolic Disease Inflammation/Immunology
    N-(p-Coumaroyl) Serotonin is a selective inhibitor of PDGFRβ, ERK1/2 and caspase-8 with antioxidant, anti-atherosclerotic and anti-inflammatory properties. N-(p-Coumaroyl) Serotonin inhibits glioblastoma cells (U251MG, T98G) with IC50 of 48-81 μM, while the IC50 for normal fibroblasts is 181-197 μM. N-(p-Coumaroyl) Serotonin inhibits PDGF signaling (reducing receptor phosphorylation), blocks Ca 2+ influx, and induces apoptosis (activating caspase-8). N-(p-Coumaroyl) Serotonin can improve atherosclerosis and aortic wall enlargement, and can also be used in the study of glioblastoma .
    N-(p-Coumaroyl) Serotonin
  • HY-N0853
    Alisol A
    4 Publications Verification

    		 AMPK Acetyl-CoA Carboxylase PPAR MMP Interleukin Related Infection Cardiovascular Disease Metabolic Disease Cancer
    Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity .
    Alisol A
  • HY-W015600
    2-Acetamidophenol

    Orthocetamol

    		 Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) LDLR Cardiovascular Disease Inflammation/Immunology
    2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe 2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .
    2-Acetamidophenol
  • HY-100401A
    Pactimibe sulfate

    CS-505

    		 Acyltransferase Cardiovascular Disease
    Pactimibe sulfate (CS-505) is a dual ACAT1/2 inhibitor with IC50s of 4.9 μM and 3.0 μM, respectively. Pactimibe sulfate (CS-505) inhibits ACAT with IC50s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively . Pactimibe sulfate (CS-505) noncompetitively inhibits oleoyl-CoA with a Ki value of 5.6 μM. Moreover, Pactimibe sulfate (CS-505) obviously inhibits cholesteryl ester formation with an IC50 of 6.7 μM. Pactimibe sulfate (CS-505) possesses anti-atherosclerotic potential with lowering plasma cholesterol activity .
    Pactimibe sulfate
  • HY-100401
    Pactimibe

    CS-505 free base

    		 Acyltransferase Cardiovascular Disease
    Pactimibe (CS-505 free base) is a dual ACAT1/2 inhibitor with IC50s of 4.9 μM and 3.0 μM, respectively. Pactimibe (CS-505 free base) inhibits ACAT with IC50s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively . Pactimibe (CS-505 free base) noncompetitively inhibits oleoyl-CoA with a Ki value of 5.6 μM. Moreover, Pactimibe (CS-505 free base) obviously inhibits cholesteryl ester formation with an IC50 of 6.7 μM. Pactimibe (CS-505 free base) possesses anti-atherosclerotic potential with lowering plasma cholesterol activity .
    Pactimibe
  • HY-N1934R
    Dihydroberberine (Standard)

    		Reference Standards Potassium Channel HSP Cardiovascular Disease Inflammation/Immunology Cancer
    Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .
    Dihydroberberine (Standard)
  • HY-B0218
    Orlistat
    Maximum Cited Publications
    18 Publications Verification

    Tetrahydrolipstatin; Ro-18-0647

    		 Fatty Acid Synthase (FASN) Apoptosis Metabolic Disease Cancer
    Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity [1]. Anti-atherosclerotic effect .
    Orlistat
  • HY-N0853R
    Alisol A (Standard)

    		Reference Standards AMPK Acetyl-CoA Carboxylase PPAR MMP Interleukin Related Infection Cardiovascular Disease Metabolic Disease Cancer
    Alisol A (Standard) is the analytical standard of Alisol A (HY-N0853). This product is intended for research and analytical applications. Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity .
    Alisol A (Standard)
  • HY-W015600R
    2-Acetamidophenol (Standard)

    Orthocetamol (Standard)

    		 Reference Standards Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) LDLR Cardiovascular Disease Inflammation/Immunology
    2-Acetamidophenol (Standard) is the analytical standard of 2-Acetamidophenol. This product is intended for research and analytical applications. 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe 2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .
    2-Acetamidophenol (Standard)
  • HY-B0218S
    Orlistat-d3

    Tetrahydrolipstatin-d3; Ro-18-0647-d3

    		 Isotope-Labeled Compounds Fatty Acid Synthase (FASN) Apoptosis Metabolic Disease
    Orlistat-d3 is a deuterated labeled Orlistat . Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity [2].?Anti-atherosclerotic?effect .
    Orlistat-d3
  • HY-N0018
    Daidzin
    5+ Cited Publications

    Daidzoside; NPI-031D; Daidzein 7-O-glucoside

    		 Mitochondrial Metabolism Reverse Transcriptase Aldehyde Dehydrogenase (ALDH) Cardiovascular Disease Others Cancer
    Daidzin is an isoflavone with antioxidant, anticancer, and antiatherosclerotic activities. Daidzin is a potent and selective inhibitor of mitochondrial ALDH-2. Daidzin reduces ethanol consumption .
    Daidzin
  • HY-N1214
    Squalene

    Super Squalene; trans-Squalene; AddaVax

    		 Endogenous Metabolite Reactive Oxygen Species (ROS) Fungal Infection Cardiovascular Disease Cancer
    Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
    Squalene
  • HY-N1214S
    Squalene-d6

    Super Squalene-d6; trans-Squalene-d6; AddaVax-d6

    		 Isotope-Labeled Compounds Others
    Squalene-d6 is a deuterium labeled Squalene. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
    Squalene-d6
  • HY-N0018R
    Daidzin (Standard)

    Daidzoside (Standard); NPI-031D (Standard); Daidzein 7-O-glucoside (Standard)

    		 Reference Standards Mitochondrial Metabolism Reverse Transcriptase Aldehyde Dehydrogenase (ALDH) Others
    Daidzin (Standard) is the analytical standard of Daidzin. This product is intended for research and analytical applications. Daidzin is an isoflavone with antioxidant, anticancer, and antiatherosclerotic activities. Daidzin is a potent and selective inhibitor of mitochondrial ALDH-2. Daidzin reduces ethanol consumption .
    Daidzin (Standard)
  • HY-N1214R
    Squalene (Standard)

    Super Squalene (Standard); trans-Squalene (Standard); AddaVax (Standard)

    		 Reference Standards Endogenous Metabolite Reactive Oxygen Species (ROS) Fungal Infection Cardiovascular Disease
    Squalene (Standard) is the analytical standard of Squalene. This product is intended for research and analytical applications. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
    Squalene (Standard)
  • HY-W005178R
    Octadecanedioic acid (Standard)

    		Reference Standards Endogenous Metabolite Others
    Solasodine (Standard) is the analytical standard of Solasodine. This product is intended for research and analytical applications. Solasodine (Purapuridine) is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities .
    Octadecanedioic acid (Standard)
  • HY-N0068R
    Solasodine (Standard)

    Purapuridine (Standard); Solancarpidine (Standard); Solasodin (Standard)

    		 Reference Standards MDM-2/p53 Fungal E1/E2/E3 Enzyme Apoptosis Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Solasodine (Standard) is the analytical standard of Solasodine. This product is intended for research and analytical applications. Solasodine (Purapuridine) is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities .
    Solasodine (Standard)
  • HY-16991
    Terutroban
    1 Publications Verification

    S-18886

    		 Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC500 of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses antiatherosclerotic and antivasoconstrictor properties .
    Terutroban
  • HY-N6642
    Ankaflavin

    		PPAR Apoptosis Inflammation/Immunology Cancer
    Ankaflavin, isolated from Monascus-Fermented red rice, is an orally active PPARγ agonist. Ankaflavin exhibits selective cytotoxic effect and induces cell death through apoptosis on cancer cells. Ankaflavin has anti-inflammatory, anti-cancer, antiatherosclerotic, and hypolipidemic effects .
    Ankaflavin
  • HY-W424839
    Probucol dithiobisphenol

    DTBP

    		 Heme Oxygenase (HO) Cardiovascular Disease
    Probucol dithiobisphenol (DTBP) is the derivative of Probucol (HY-B0388). Probucol dithiobisphenol induces the production of heme oxygenase 1 (HO-1), and exhibits antioxidant activity. Probucol dithiobisphenol inhibits atherosclerotic lesions in Apoe −/− mice aorta, promotes re-endothelialization of aorta and inhibits restenosis in rabbit arterial injury models. Probucol dithiobisphenol is orally active .
    Probucol dithiobisphenol
  • HY-149120
    ASM-IN-1

    		Phospholipase Cardiovascular Disease Inflammation/Immunology
    ASM-IN-1 is a potent and orally active acid sphingomyelinase (ASM) inhibitor with an IC50 value of 1.5 µM. ASM-IN-1 reduces lipid plaques in the aortic arch and aorta and reduces plasma ceramide concentration and Ox-LDL levels. ASM-IN-1 shows antiatherosclerotic and anti-inflammatory activity .
    ASM-IN-1
  • HY-114348
    N,N'-Diacetyl-L-cystine

    DiNAC; (Ac-Cys-OH)2

    		 Amino Acid Derivatives Cardiovascular Disease
    N,N'-diacetyl-L-cystine (DiNAC) is the disulphide dimer of N-acetylcysteine with immunomodulating properties. N,N'-diacetyl-L-cystine is a potent, orally active modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. N,N'-diacetyl-L-cystine also has antiatherosclerotic effects in Watanabe-heritable hyperlipidemic rabbit (WHHL) rabbits .
    N,N'-Diacetyl-L-cystine
  • HY-16991R
    Terutroban (Standard)

    		Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Terutroban (Standard) is the analytical standard of Terutroban. This product is intended for research and analytical applications. Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC500 of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses antiatherosclerotic and antivasoconstrictor properties .
    Terutroban (Standard)
  • HY-107396
    YM-750

    		Acyltransferase Cardiovascular Disease
    YM-750 is a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor (IC50=0.18 μM). ACAT catalyzes the formation of cholesteryl esters from cholesterol and long-chain fatty-acyl-coenzyme A .
    YM-750
  • HY-N0068
    Solasodine
    3 Publications Verification

    Purapuridine; Solancarpidine; Solasodin

    		 MDM-2/p53 Fungal E1/E2/E3 Enzyme Apoptosis Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Solasodine (Purapuridine) is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine induces apoptosis by inhibiting the p53-MDM2 complex, p21Waf1/Cip1, and Bcl-2 proteins. Solasodine has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities .
    Solasodine
  • HY-W751400
    Solasodine hydrochloride

    Purapuridine hydrochloride; Solancarpidine hydrochloride; Solasodin hydrochloride

    		 MDM-2/p53 E1/E2/E3 Enzyme Fungal Apoptosis Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Solasodine (Purapuridine) hydrochloride is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine hydrochloride induces apoptosis by inhibiting the p53-MDM2 complex, p21Waf1/Cip1, and Bcl-2 proteins. Solasodine hydrochloride has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities .
    Solasodine hydrochloride
  • HY-N0236
    Corylin
    5 Publications Verification

    		 Antibiotic STAT Infection Metabolic Disease Cancer
    Corylin is an orally active flavonoid anti-inflammatory and osteogenic agent that inhibits IL-6-induced STAT3 promoter activity and STAT3 phosphorylation. Corylin also has anticancer, antiatherosclerotic, and ameliorating activity in hyperlipidemia and insulin resistance, inducing adipocyte browning and lipolysis through SIRT1 or β3-AR-dependent pathways .
    Corylin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: